The randomized, double-blind, placebo-controlled trial has been conducted at 67 oncology centers across the U.S. The trial has enrolled both treatment-naive and relapsed/refractory patients with stable or responding disease following treatment with Rituxan.
“The rapid enrollment supports our belief that an all-biologic regimen of Rituxan followed by FavId could, if approved, become the option preferred by patients with indolent B-cell NHL who wish to avoid many of the side effects associated with chemotherapy,” said Dr John Bender, senior vice-president of Clinical Research.
In addition, the FDA has granted fast track designation for the drug indicating that the FDA will expedite the review of the drug.
Favrille is a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer.